Rx-To-OTC Switches "Not In Financial Interests" Of Manufacturers - Juhl
This article was originally published in The Tan Sheet
Executive Summary
Three years of market exclusivity following an Rx-to-OTC switch might not be enough of an incentive to encourage manufacturers to apply for switches, former FDA Nonprescription Drugs Advisory Committee chair Randy Juhl, PhD, University of Pittsburgh, suggested at the American Pharmaceutical Association annual meeting March 11.
You may also be interested in...
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
An initiative promoting Prilosec OTC over prescription competitors to help Medicare Part D users avoid "the coverage gap" in their prescription costs may prompt a closer look at ways Medicare can pay for OTCs
OTC Cholesterol Drugs May Be Revisited By FDA In 2000
FDA will re-examine the question of potential Rx-to-OTC switches of hypercholesterolemia drugs in 2000, including reexamination of a 1997 guidance finding such drugs inappropriate for over-the-counter sale, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Dec. 16.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC